What is Harvard Bioscience Inc worth?
With the base-case assumptions below, a discounted cash flow model on Harvard Bioscience Inc's reported free cash flow gives $0.68 per share. The share price was $7.96 on September 25, 2026, 1,069% above that value.
Inputs from the filings
Three sets of assumptions
| Case | Growth yrs 1-5 | Discount rate | Value per share | Value vs price |
|---|---|---|---|---|
| Bear | -8.5% | 10.0% | $0.19 | -98% |
| Base | -3.5% | 9.0% | $0.68 | -91% |
| Bull | 1.5% | 8.0% | $1.65 | -79% |
Sensitivity: base case value per share
| 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | |
|---|---|---|---|---|---|
| 7.0% | $1.02 | $1.12 | $1.24 | $1.39 | $1.59 |
| 8.0% | $0.77 | $0.83 | $0.91 | $1.00 | $1.11 |
| 9.0% | $0.59 | $0.63 | $0.68 | $0.74 | $0.81 |
| 10.0% | $0.45 | $0.48 | $0.51 | $0.55 | $0.60 |
| 11.0% | $0.33 | $0.36 | $0.38 | $0.41 | $0.44 |
Where the presets come from
Base: years 1 to 5 grow at Harvard Bioscience Inc's revenue growth rate over the last 5 fiscal years (-3.3% a year), held between -5% and 15%. Years 6 to 10 grow halfway between that and the long-run rate of 2.5%. Future cash is discounted at 9% a year.
Bear: 5 points less growth, 2% long-run growth, 10% discount rate. Bull: 5 points more growth (at most 25%), 3% long-run growth, 8% discount rate.
Value per share = (present value of 10 years of free cash flow + present value of everything after + cash - debt) / diluted shares.
This is a model run on assumptions, not a recommendation or a price target. Small changes in the discount rate or growth move the result a lot, as the table above shows. Change them yourself in the calculator.
Adjust the assumptions
Move the sliders for growth, long-run growth and discount rate, or switch to average free cash flow, and see the value per share change.
Adjust the assumptions